Aside from ibrutinib, patients with M-CLL, devoid of TP53 aberrations and in shape ample to tolerate FCR therapy, may still be superior candidates with the latter, While using the gain getting that this treatment might be accomplished in six months though ibrutinib need to be taken indefinitely. This selection might be particularly worthwhile for n